CLINICAL TRIALS PROFILE FOR TRODELVY

Biosimilar Clinical Trials for TRODELVY

This table shows clinical trials for biosimilars. See the next table for all clinical trials

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT06100874 ↗	A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)	Recruiting	Gilead Sciences	Phase 2	2023-11-20	This research study is being done to evaluate the safety and effectiveness of sacituzumab govitecan with trastuzumab (Herceptin, Herceptin Hylecta, or trastuzumab biosimilar) in metastatic HER2+ breast cancer. The names of the study drugs used in this research study are: - Sacituzumab govitecan (a type of antibody-drug conjugate) - Trastuzumab (Herceptin) (a type of monoclonal antibody) - Trastuzumab and Hyaluronidase-oysk (Herceptin Hylecta) (a type of recombinant monoclonal antibody) - Trastuzumab biosimilar drug
NCT06100874 ↗	A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)	Recruiting	Adrienne G. Waks	Phase 2	2023-11-20	This research study is being done to evaluate the safety and effectiveness of sacituzumab govitecan with trastuzumab (Herceptin, Herceptin Hylecta, or trastuzumab biosimilar) in metastatic HER2+ breast cancer. The names of the study drugs used in this research study are: - Sacituzumab govitecan (a type of antibody-drug conjugate) - Trastuzumab (Herceptin) (a type of monoclonal antibody) - Trastuzumab and Hyaluronidase-oysk (Herceptin Hylecta) (a type of recombinant monoclonal antibody) - Trastuzumab biosimilar drug

All Clinical Trials for TRODELVY

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT03971409 ↗	Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Patients With Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer	Recruiting	Array BioPharma	Phase 2	2019-07-08	This phase II trial studies how well the combination of avelumab with liposomal doxorubicin with or without binimetinib, or the combination of avelumab with sacituzumab govitecan works in treating patients with triple negative breast cancer that is stage IV or is not able to be removed by surgery (unresectable) and has come back (recurrent). Immunotherapy with checkpoint inhibitors like avelumab require activation of the patient's immune system. This trial includes a two week induction or lead-in of medications that can stimulate the immune system. It is our hope that this induction will improve the response to immunotherapy with avelumab. One treatment, sacituzumab Govitecan, is a monoclonal antibody called sacituzumab linked to a chemotherapy drug called SN-38. Sacituzumab govitecan is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of tumor cells, known as Tumor-associated calcium signal transducer 2 (TROP2) receptors, and delivers SN-38 to kill them. Another treatment, liposomal doxorubicin, is a form of the anticancer drug doxorubicin that is contained in very tiny, fat-like particles. It may have fewer side effects and work better than doxorubicin, and may enhance factors associated with immune response. The third medication is called binimetinib, which may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth, and may help activate the immune system. It is not yet known whether giving avelumab in combination with liposomal doxorubicin with or without binimetinib, or the combination of avelumab with sacituzumab govitecan will work better in treating patients with triple negative breast cancer.
NCT03971409 ↗	Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Patients With Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer	Recruiting	Breast Cancer Research Foundation	Phase 2	2019-07-08	This phase II trial studies how well the combination of avelumab with liposomal doxorubicin with or without binimetinib, or the combination of avelumab with sacituzumab govitecan works in treating patients with triple negative breast cancer that is stage IV or is not able to be removed by surgery (unresectable) and has come back (recurrent). Immunotherapy with checkpoint inhibitors like avelumab require activation of the patient's immune system. This trial includes a two week induction or lead-in of medications that can stimulate the immune system. It is our hope that this induction will improve the response to immunotherapy with avelumab. One treatment, sacituzumab Govitecan, is a monoclonal antibody called sacituzumab linked to a chemotherapy drug called SN-38. Sacituzumab govitecan is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of tumor cells, known as Tumor-associated calcium signal transducer 2 (TROP2) receptors, and delivers SN-38 to kill them. Another treatment, liposomal doxorubicin, is a form of the anticancer drug doxorubicin that is contained in very tiny, fat-like particles. It may have fewer side effects and work better than doxorubicin, and may enhance factors associated with immune response. The third medication is called binimetinib, which may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth, and may help activate the immune system. It is not yet known whether giving avelumab in combination with liposomal doxorubicin with or without binimetinib, or the combination of avelumab with sacituzumab govitecan will work better in treating patients with triple negative breast cancer.
NCT03971409 ↗	Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Patients With Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer	Recruiting	Hoosier Cancer Research Network	Phase 2	2019-07-08	This phase II trial studies how well the combination of avelumab with liposomal doxorubicin with or without binimetinib, or the combination of avelumab with sacituzumab govitecan works in treating patients with triple negative breast cancer that is stage IV or is not able to be removed by surgery (unresectable) and has come back (recurrent). Immunotherapy with checkpoint inhibitors like avelumab require activation of the patient's immune system. This trial includes a two week induction or lead-in of medications that can stimulate the immune system. It is our hope that this induction will improve the response to immunotherapy with avelumab. One treatment, sacituzumab Govitecan, is a monoclonal antibody called sacituzumab linked to a chemotherapy drug called SN-38. Sacituzumab govitecan is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of tumor cells, known as Tumor-associated calcium signal transducer 2 (TROP2) receptors, and delivers SN-38 to kill them. Another treatment, liposomal doxorubicin, is a form of the anticancer drug doxorubicin that is contained in very tiny, fat-like particles. It may have fewer side effects and work better than doxorubicin, and may enhance factors associated with immune response. The third medication is called binimetinib, which may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth, and may help activate the immune system. It is not yet known whether giving avelumab in combination with liposomal doxorubicin with or without binimetinib, or the combination of avelumab with sacituzumab govitecan will work better in treating patients with triple negative breast cancer.
NCT03971409 ↗	Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Patients With Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer	Recruiting	Johns Hopkins University	Phase 2	2019-07-08	This phase II trial studies how well the combination of avelumab with liposomal doxorubicin with or without binimetinib, or the combination of avelumab with sacituzumab govitecan works in treating patients with triple negative breast cancer that is stage IV or is not able to be removed by surgery (unresectable) and has come back (recurrent). Immunotherapy with checkpoint inhibitors like avelumab require activation of the patient's immune system. This trial includes a two week induction or lead-in of medications that can stimulate the immune system. It is our hope that this induction will improve the response to immunotherapy with avelumab. One treatment, sacituzumab Govitecan, is a monoclonal antibody called sacituzumab linked to a chemotherapy drug called SN-38. Sacituzumab govitecan is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of tumor cells, known as Tumor-associated calcium signal transducer 2 (TROP2) receptors, and delivers SN-38 to kill them. Another treatment, liposomal doxorubicin, is a form of the anticancer drug doxorubicin that is contained in very tiny, fat-like particles. It may have fewer side effects and work better than doxorubicin, and may enhance factors associated with immune response. The third medication is called binimetinib, which may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth, and may help activate the immune system. It is not yet known whether giving avelumab in combination with liposomal doxorubicin with or without binimetinib, or the combination of avelumab with sacituzumab govitecan will work better in treating patients with triple negative breast cancer.
NCT03971409 ↗	Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Patients With Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer	Recruiting	Pfizer	Phase 2	2019-07-08	This phase II trial studies how well the combination of avelumab with liposomal doxorubicin with or without binimetinib, or the combination of avelumab with sacituzumab govitecan works in treating patients with triple negative breast cancer that is stage IV or is not able to be removed by surgery (unresectable) and has come back (recurrent). Immunotherapy with checkpoint inhibitors like avelumab require activation of the patient's immune system. This trial includes a two week induction or lead-in of medications that can stimulate the immune system. It is our hope that this induction will improve the response to immunotherapy with avelumab. One treatment, sacituzumab Govitecan, is a monoclonal antibody called sacituzumab linked to a chemotherapy drug called SN-38. Sacituzumab govitecan is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of tumor cells, known as Tumor-associated calcium signal transducer 2 (TROP2) receptors, and delivers SN-38 to kill them. Another treatment, liposomal doxorubicin, is a form of the anticancer drug doxorubicin that is contained in very tiny, fat-like particles. It may have fewer side effects and work better than doxorubicin, and may enhance factors associated with immune response. The third medication is called binimetinib, which may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth, and may help activate the immune system. It is not yet known whether giving avelumab in combination with liposomal doxorubicin with or without binimetinib, or the combination of avelumab with sacituzumab govitecan will work better in treating patients with triple negative breast cancer.
NCT03971409 ↗	Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Patients With Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer	Recruiting	Translational Breast Cancer Research Consortium	Phase 2	2019-07-08	This phase II trial studies how well the combination of avelumab with liposomal doxorubicin with or without binimetinib, or the combination of avelumab with sacituzumab govitecan works in treating patients with triple negative breast cancer that is stage IV or is not able to be removed by surgery (unresectable) and has come back (recurrent). Immunotherapy with checkpoint inhibitors like avelumab require activation of the patient's immune system. This trial includes a two week induction or lead-in of medications that can stimulate the immune system. It is our hope that this induction will improve the response to immunotherapy with avelumab. One treatment, sacituzumab Govitecan, is a monoclonal antibody called sacituzumab linked to a chemotherapy drug called SN-38. Sacituzumab govitecan is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of tumor cells, known as Tumor-associated calcium signal transducer 2 (TROP2) receptors, and delivers SN-38 to kill them. Another treatment, liposomal doxorubicin, is a form of the anticancer drug doxorubicin that is contained in very tiny, fat-like particles. It may have fewer side effects and work better than doxorubicin, and may enhance factors associated with immune response. The third medication is called binimetinib, which may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth, and may help activate the immune system. It is not yet known whether giving avelumab in combination with liposomal doxorubicin with or without binimetinib, or the combination of avelumab with sacituzumab govitecan will work better in treating patients with triple negative breast cancer.

Clinical Trial Conditions for TRODELVY

Condition Name

Condition Name for TRODELVY
Intervention	Trials
Triple Negative Breast Cancer	7
Breast Cancer	4
Metastatic Breast Cancer	4
HER2-negative Breast Cancer	3

Condition MeSH

Condition MeSH for TRODELVY
Intervention	Trials
Breast Neoplasms	15
Triple Negative Breast Neoplasms	8
Carcinoma	4
Urinary Bladder Neoplasms	3

Clinical Trial Locations for TRODELVY

Trials by Country

Trials by Country for TRODELVY
Location	Trials
United States	30
Germany	15
Spain	10
Australia	5
Taiwan	2

Trials by US State

Trials by US State for TRODELVY
Location	Trials
Massachusetts	7
Illinois	3
Ohio	2
Texas	2
Tennessee	2

Clinical Trial Progress for TRODELVY

Clinical Trial Phase

Clinical Trial Phase for TRODELVY
Clinical Trial Phase	Trials
PHASE3	1
PHASE2	1
Phase 3	3

Clinical Trial Status

Clinical Trial Status for TRODELVY
Clinical Trial Phase	Trials
Recruiting	14
Not yet recruiting	10

Clinical Trial Sponsors for TRODELVY

Sponsor Name

Sponsor Name for TRODELVY
Sponsor	Trials
Gilead Sciences	14
Immunomedics, Inc.	4
Dana-Farber Cancer Institute	4

Sponsor Type

Sponsor Type for TRODELVY
Sponsor	Trials
Industry	32
Other	31
NIH	1

TRODELVY (sacituzumab govitecan) Clinical Trials Update, Market Analysis and Revenue Projection

Last updated: July 25, 2026

Executive summary

• Trodelvy (sacituzumab govitecan-hziy) is a Trop-2 directed antibody-drug conjugate (ADC) with a core commercial engine in metastatic triple-negative breast cancer (mTNBC) and metastatic urothelial cancer (mUC).
• The most commercially relevant label is the mTNBC line expanded beyond the pivotal ASCENT trial setting (including post-chemotherapy use) and the mUC program supported by the TROPiCS-04 regimen evolution and earlier approvals.
• Near-term commercial trajectory depends on (1) conversion of treatment patterns toward combination regimens, (2) durability of response in real-world use, and (3) the pace of new trial readouts that can broaden indications and/or reposition lines of therapy.
• A practical revenue model is sensitive to: addressable population size, dose intensity, discontinuation rate, and competition from next-generation ADCs (Trop-2 and other targets) and from chemoimmunotherapy.

---

What is TRODELVY used for in the US and what lines of therapy drive revenue?

Featured snippet answer: Trodelvy is used for metastatic triple-negative breast cancer (mTNBC) after prior therapies and for metastatic urothelial cancer (mUC) after prior treatment, with dosing delivered in 21-day cycles.

Key US commercial indications

Trodelvy’s revenue is concentrated in:

• mTNBC settings where Trop-2 expression and ADC response rates translate to clinically meaningful outcomes versus subsequent chemotherapy.
• mUC settings where options are limited after platinum and immunotherapy, making later-line ADC uptake more rapid than first-line agents.

Dosing and treatment cycle structure

• Trodelvy is administered on a schedule tied to 21-day cycles (days vary by regimen).
• The commercial impact is driven by time on treatment, which depends on toxicity profile (notably neutropenia, diarrhea, and nausea), dose reductions, and discontinuation rates.

---

How has TRODELVY’s clinical trial program evolved since approval?

Featured snippet answer: The clinical program has shifted from single-agent validation toward regimen expansion, including earlier-line positioning and combination studies.

Core study types shaping market growth

1. Phase 3 registrational efforts
   These determine whether label expansion occurs into additional lines and new subtypes (including combination roles).
2. Phase 1/2 expansion and biomarker-enriched work
   These identify which combinations and patient subsets show the best risk-benefit, supporting payer adoption and clinician uptake.
3. Real-world implementation studies
   While not label changing, these affect persistence, dose intensity, and overall effective utilization.

Most market-relevant development axes

• Earlier line of therapy: If Trodelvy moves toward earlier metastatic settings, the addressable pool grows.
• Combination regimens: Combinations can improve response and may support broader physician adoption, but can also increase toxicity and cost.
• Biomarker strategy: Trop-2 expression may guide patient selection; a clearer biomarker strategy reduces “therapeutic uncertainty,” improving uptake.

---

Which ongoing TRODELVY clinical trials are most likely to change label positioning?

Featured snippet answer: Trials targeting first-line metastatic settings, combination regimens, and additional metastatic subtypes have the highest probability of shifting market share.

High-impact trial categories

• mTNBC combination expansion
  • Designs that pair Trodelvy with immunotherapy or other systemic agents can shift it from later-line to mid-line or earlier.
• mUC sequencing studies
  • Studies that place Trodelvy earlier in mUC sequences can expand commercial volume and improve retention through longer average treatment duration.
• Mechanism-expanding studies across solid tumors
  • Any positive readouts outside breast and urothelial cancer can create incremental demand, but magnitude typically depends on registrational endpoints and biomarker-defined populations.

What to watch in readouts

• Overall survival vs comparator in phase 3 work
• Progression-free survival and response rate
• Toxicity and dose intensity
• Subgroup consistency (particularly for Trop-2 expression strata)

Clinical-trial update constraint: A precise trial-by-trial update requires current publicly reported results (trial numbers, endpoints, readout dates, and outcomes). That level of detail is not provided in the prompt, so it cannot be reproduced here without risking factual errors.

---

What patents protect TRODELVY and how strong is the patent estate?

Featured snippet answer: Trodelvy’s intellectual property includes ADC composition/chemical entities, linker-payload embodiments, methods of manufacture, and potentially method-of-use and formulation claims that can extend exclusivity and deter generic and biosimilar-style competition.

Patent estate components that drive litigation risk

• Drug substance claims
  • Antibody-drug conjugate structure, conjugation chemistry, and payload definitions.
• Linker and payload claims
  • Linker-payload combinations and payload release/structure protections.
• Manufacturing and conjugation process claims
  • Procedures controlling DAR, purification steps, and process parameters.
• Method-of-use claims
  • Label-aligned regimens and dosing schedules can create enforcement hooks even if composition claims are challenged.

How patent strength affects the commercial curve

• Stronger composition and process claims reduce likelihood of early generic entry (small-molecule style) and increase the expected duration of exclusivity-like market stability for “next-available” ADC entrants.
• Process and batch-consistency IP can raise barriers to any “follow-on” ADC developer seeking regulatory approval via bridge datasets.

Patent-specific constraint: A definitive list of TRODELVY patent numbers, filing/expiration dates, and assignees cannot be provided because the prompt does not include a patent docket, Orange Book entries, or a dossier reference.

---

What is the Orange Book status of TRODELVY and what does it mean for generic entry risk?

Featured snippet answer: Trodelvy is not a traditional small-molecule with a straightforward generic pathway; generic “entry risk” is more constrained and generally depends on the feasibility of biosimilar-like ADC development and any allowable regulatory pathway that fits the product’s biologic nature.

Expected competitive pathways

• Generics
  • Typically not applicable in a standard manner for ADCs with biologic components and proprietary conjugation processes.
• Follow-on ADCs
  • Realistic competitive threats come from “me-too” ADCs with comparable targets and different payloads/linkers, cleared through clinical evidence.

Orange Book constraint: Without the Orange Book listing details (application numbers, listed patents, and expiration dates), a correct Orange Book status summary cannot be produced.

---

How does TRODELVY compare with competing ADCs and standard-of-care in mTNBC and mUC?

Featured snippet answer: Trodelvy competes primarily against ADCs targeting Trop-2 and other solid-tumor ADC platforms, plus standard chemotherapies and immunotherapy combinations depending on line of therapy.

Competitive comparison drivers

• Efficacy magnitude
  • Response rates, duration of response, and survival endpoints relative to comparator regimens.
• Safety and manageability
  • Neutropenia, diarrhea, fatigue, and nausea management affects dose persistence and real-world effectiveness.
• Dosing convenience
  • Clinic scheduling and monitoring burden influence adoption.
• Sequence positioning
  • Which agents are used immediately before Trodelvy determines whether patients reach it with sufficient performance status.

Market share sensitivity

• If competing ADCs show better tolerability or higher durability in post-platinum or post-immunotherapy populations, Trodelvy share can compress even if overall category growth continues.

---

When does TRODELVY lose exclusivity and what is the forecast impact?

Featured snippet answer: Loss of exclusivity is a function of the expiration of composition/process patents plus any regulatory exclusivity periods; forecast impact typically shows up as accelerated competitive penetration beginning once patent barriers weaken.

Forecast mechanics

• Revenue doesn’t drop to zero at exclusivity loss. It declines based on:
  • How quickly payers change preferred coverage,
  • How quickly clinicians switch given toxicity management experience,
  • The clinical performance of competitors and availability.

Exclusivity-timing constraint: Specific exclusivity dates cannot be stated because the prompt does not provide the relevant patent expiration or regulatory exclusivity records.

---

How big is the TRODELVY market and what adoption curve supports revenue projection?

Featured snippet answer: Trodelvy’s market size is driven by mTNBC and mUC incidence, the proportion eligible after prior therapy, and duration of treatment. The adoption curve depends on trial uptake into routine sequencing and ability to manage adverse events.

Revenue projection model framework (structure)

A workable projection splits revenue into:

• Treated patients
  • Eligible population × lines of therapy reaching Trodelvy
• Treatment duration
  • Median time on therapy and distribution tails
• Dose intensity
  • Dose reductions and cycle delays
• Net price
  • Contracting, rebates, and mix effects

Scenario approach (what moves the number)

• Base case
  • Modest expansion in eligible lines, stable persistence, incremental share in mUC.
• Upside
  • Positive phase 3 results expand label earlier in metastatic disease, improving penetration.
• Downside
  • Competitive ADCs with stronger efficacy or better tolerability displace Trodelvy in key lines; persistence shortens.

Quantitative market-size constraint: The prompt does not include current financials (company revenue by indication, unit sales, or treatment counts), nor incidence statistics, nor net pricing. Without those inputs, a numerical forecast would require fabricating assumptions, which cannot be done.

---

What commercial KPIs should investors track for TRODELVY?

Featured snippet answer: Unit growth, persistence/time-on-treatment, average dose intensity, and net price per cycle are the KPIs that most directly map to revenue.

KPI checklist

• Prescription growth
• New-to-brand share in mTNBC and mUC
• Dose reduction rate
• Cycle delays
• Discontinuation rate for toxicity
• Indication mix shift
• Contracting and net-to-gross
• Real-world response durability proxies

---

What is the most likely litigation and settlement landscape affecting TRODELVY?

Featured snippet answer: ADC litigation typically centers on composition/process and method-of-use claims; settlements can delay competitive entry and preserve branded revenue for defined periods.

Litigation constraint: No litigation docket, parties, or case numbers are included in the prompt. A correct litigation summary cannot be produced.

---

Key Takeaways

• Trodelvy’s commercial base is anchored in mTNBC and mUC lines where ADC activity and limited later-line alternatives support durable demand.
• The highest probability growth drivers are label expansions from combination and earlier-line clinical readouts, plus sustained real-world dose management that preserves treatment duration.
• Revenue projections hinge on treated-patient volume, persistence, dose intensity, and net pricing; competitive ADC entrants can compress adoption even as category demand grows.
• Exact patent, exclusivity, Orange Book, and litigation timelines require docket-accurate inputs not included in the prompt, so they are not enumerated here.

---

FAQs

1. How do Trop-2 expression and patient selection affect real-world uptake of TRODELVY in mTNBC?
2. What toxicity-management practices most influence TRODELVY dose intensity and persistence?
3. Which next-generation ADCs pose the greatest share risk to TRODELVY in second-line and later-line settings?
4. How do combination regimens change the cost and payer coverage dynamics for TRODELVY?
5. What endpoints best predict whether TRODELVY trial results will support earlier-line label expansion?

---

References

1. No sources were provided in the prompt.